A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Omniscan Side Effects, and Drug Interactions - Gadodiamide
Omniscan Side Effects, and Drug Interactions - Gadodiamide
SIDE EFFECTS
The most frequent adverse events observed during OMNISCAN clinical
trials were nausea, headache, and dizziness that occurred in 3% or less of the
patients; other adverse events that occurred in 1% or less of the patients are
listed below. This includes all reported adverse events regardless of attribution.
The majority of these adverse events were of mild to moderate intensity. Dose
and adverse event relationships are not fully clarified.
The following adverse events occurred in 1% or less of the
patients:
Application Site Disorders: Injection site reaction.
Autonomic Nervous System Disorders: Vasodilation.
Body as a Whole-General Disorders: Anaphylactoid
reactions (characterized by cardiovascular, respiratory, and cutaneous symptoms),
asthenia, chest pain, fatigue, fever, hot flushes, malaise, pain, rigors, syncope.
Cardiovascular Disorders: Cardiac failure, rare
arrhythmia and myocardial infarction resulting in death in patients with ischemic
heart disease, flushing, deep thrombophlebitis.
Central and Peripheral Nervous System Disorders: Aggravated
migraine, ataxia, convulsions (including grand mal), abnormal coordination,
aggravated multiple sclerosis (characterized by sensory and motor disturbances),
paresthesia, tremor.
Gastrointestinal System Disorders: Abdominal
pain, diarrhea, eructation, melena, dry mouth, vomiting.
Hearing and Vestibular Disorders: Tinnitus.
Liver and Biliary System Disorders: Abnormal
hepatic function.
Musculoskeletal System Disorders: Arthralgia,
myalgia.
Psychiatric Disorders: Anorexia, anxiety, personality
disorder, somnolence.
Respiratory System Disorders: Rhinitis, dyspnea.
Skin and Appendage Disorders: Pruritus, rash,
erythematous rash, skin discoloration, sweating increased, urticaria.
Special Senses, Other Disorders: Taste loss,
taste perversion.
Urinary System Disorders: Acute reversible renal
failure.
Vision Disorders: Abnormal vision.
DRUG INTERACTIONS
LABORATORY TEST FINDINGS
Asymptomatic, transitory changes in serum iron have been observed.
The clinical significance is unknown.
Omniscan interferes with serum calcium measurements with some
colorimetric (complexometric) methods commonly used in hospitals, resulting
in serum calcium concentrations lower than the true values. Thus, it is recommended
not to use such methods for 12-24 hours after administration of Omniscan. If
such measurements are necessary, the use of other methods is recommended. All
patients in whom this effect was observed remained asymptomatic.
top
